East Hanover, N.J., June 30, 2022 — Novartis today announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. FLG client, Kedalion Therapeutics, is a clinical-stage,…Read More
“I’ve had the fortunate opportunity to work closely with Mark Murray of FLG Partners in a series of four successful venture backed -backed companies in Silicon Valley over the past dozen years including Optimedica Corporation, Oculeve, Oyster Point Pharmaceuticals and most recently Kedalion Therapeutics. I consider him to be the consummate professional and invaluable in providing state of the art financial management and strategic advising for young rapidly growing drug and medical device companies. Mark has a wealth of experience and considerable savvy in a variety of different situations and market conditions, whether it be in developing a strategic plan, raising capital, optimizing operations or helping identify and manage liquidity events. In my mind he is an absolute go-to thinker and do-er for any company looking to attract top level management talent.”
Mark S. Blumenkranz, CEO & Chairman, Kedalion Therapeutics Read More